Month: June 2019

PTC299 is an Oral Active and Dual Inhibitor of DHODH and VEGF

De novo pyrimidine nucleotide biosynthesis is activated in proliferating cancer cells in response to an increased demand for synthesis of DNA, RNA and phospholipids. The synthesis activates via oncogenic pathways, such as Myc, PI3K, PTEN and mTOR. Dihydroorotate dehydrogenase (DHODH) locates on the surface of the inner mitochondrial membrane,...

MA242 is a Dual Inhibitor of MDM2 and NFAT1

Overexpression and activation of the murine double minute 2 (MDM2) or nuclear factor of activated T cells 1 (NFAT1) oncoproteins occur frequently in pancreatic cancer. Many MDM2 inhibitors target MDM2-p53 binding and have little or no effect on cancers without functional p53, such as pancreatic cancer. Besides, nuclear factor...